Autologous Stem Cell and Non-Stem Cell Based Therapies Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 110 Pages | 納期: 2~3営業日

価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=137.14円
出版日: 2022年01月17日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 110 Pages
納期: 2~3営業日
● ご注意事項
  • 全表示
  • 概要
  • 目次





第1章 イントロダクション

  • 調査成果
  • 調査の前提条件
  • 調査範囲

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概要
  • 市場成長要因
    • 標的疾患の有病率の上昇
    • 再生医療における新しい自家幹細胞ベースの治療法のイントロダクション
    • 高齢者人口の増加
  • 市場の抑制要因
    • 自己細胞療法の高コスト
    • 熟練した専門家の不足
  • ポーターのファイブフォース分析
    • 新規参入の脅威
    • バイヤー/消費者の交渉力
    • サプライヤーの交渉力
    • 代替製品の脅威
    • 競争の激化

第5章 市場細分化

  • タイプ別
    • 自家幹細胞
    • 非幹細胞
  • 用途別
    • 神経変性疾患
    • 循環器疾患
    • 自己免疫疾患
    • その他
  • エンドユーザー別
    • 病院
    • 外来手術センター
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ地域
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Antria, Inc.
    • BrainStorm Cell Limited.
    • Caladrius
    • Cytori Therapeutics Inc.
    • Dendreon Pharmaceuticals LLC
    • Fibrocell Science, Inc,
    • Orgenesis Inc.
    • Regeneus Ltd
    • US Stem Cell, Inc,

第7章 市場機会および将来動向

Product Code: 67855

Key Highlights

  • The Autologous Stem Cell and Non-Stem Cell-Based Therapies market is anticipated to grow with a CAGR of nearly 14.26%, during the forecast period. Certain factors that are driving the market growth include rising prevalence of targeted diseases, the introduction of novel autologous stem cell-based therapies in regenerative medicine and increasing of the geriatric population.
  • Stem cell technology is found to be a speedily developing technology which plays a major role in regenerative medicine, as it also serves the disciplines of tissue engineering, developmental cell biology, cellular therapeutics, gene therapy, chemical biology, and nanotechnology. Stem cells offer the possibility of replacing the cells and tissues to treat various conditions including spinal cord injury, arthritis, and Parkinson's disease, among others.
  • The applications of stem cell technologies in the treatment of diseases have ultimately increased the overall adoption rate of these technologies across the world.
  • The advantage of autologous stem cell transplant is that one is getting one's own cells back. This means there is no risk that the immune system of the individual will reject the transplant or that the transplanted cells will attack or reject the individual's body.

Key Market Trends

Cancer Holds Significant Share in the Autologous Stem Cell and Non-Stem Cell Based Therapies Market

  • Cancer rates could further increase by 50%, to 15 million new cases by 2020, as per World Cancer Report. It also provides clear evidence that healthy lifestyles and public health action by governments and health practitioners could stem this trend, and prevent as many as one-third of cancers, worldwide.
  • The American Cancer Society, the leading body in cancer stats and figures, reports 1,685,210 estimated new cancer cases and 595,690 deaths due to cancer in 2016, in the United States.
  • The National Cancer Institute reports that more than 60% of the world's new cancer cases occur in Africa, Asia, and Central and South America; 70% of the world's cancer deaths also occur in these regions. The International Agency for Research on Cancer (IARC) predicts that by 2030, the global burden is expected to rise to 21.7 million new cancer cases and 13 million cancer deaths, simply due to growth and aging of population, leaving aside factors, such as smoking, poor diet, physical inactivity, and fewer childbirths in economically developing countries.
  • According to WHO, almost 70% of deaths from cancer occur in low and middle-income countries, and only one in five low- and middle-income countries has the necessary data to drive cancer policy. This global and extensive threat of cancer remains a major market driver for new cancer therapies that help in risk assessment, early diagnosis, and effective monitoring of the treatment.

North America Dominates the Autologous Stem Cell and Non-Stem Cell Based Therapies Market

  • North America dominated the overall stem cell market with the United States contributing to the largest share in the market.
  • The ease in the US government regulations and availability of funds from various organizations, like the National Institute of Health, have provided the potential for researchers to invest more in the use of biomarkers in drug discovery, drug development, detection of specific tumors, monitoring biological response to cancer therapy, and genetic studies for the identification of predisposed candidates of cancer.
  • In 2014, the Sanford Stem Cell Clinical Center at the University of California, San Diego (UCSD) Health System, announced the launch of a clinical trial, in order to assess the safety of neural stem cell-based therapy in patients with chronic spinal cord injury.
  • Researchers hoped that the transplanted stem cells may develop into new neurons that could replace severed or lost nerve connections, and restore at least some motor and sensory functions. Such numerous stem cell studies across the United States have helped in the growth of the stem cell market.

Competitive Landscape

The global Autologous Stem Cell and Non-Stem Cell-Based Therapies market is competitive and consists of a few major players. The companies includes Novartis AG, BrainStorm Cell Limited, Caladrius, Cytori Therapeutics Inc., Dendreon Pharmaceuticals LLC, Gilead Sciences Inc., Regeneus Ltd, U.S. Stem Cell, Inc, among others, hold the substantial market share in the growth of overall market.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support



  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Targeted Diseases
    • 4.2.2 Introduction of Novel Autologous Stem Cell Based Therapies in Regenerative Medicine
    • 4.2.3 Increasing Geriatric Population
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Autologous Cellular Therapies
    • 4.3.2 Lack of Skilled Professionals
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Type
    • 5.1.1 Autologous Stem Cells
    • 5.1.2 Autologous Non-Stem cells
  • 5.2 By Application
    • 5.2.1 Cancer
    • 5.2.2 Neurodegenerative Disorders
    • 5.2.3 Cardiovascular Disease
    • 5.2.4 Orthopedic Diseases
    • 5.2.5 Others
  • 5.3 By End-User
    • 5.3.1 Hospitals
    • 5.3.2 Ambulatory Surgical Centers
    • 5.3.3 Research Facilities
  • 5.4 Geography
    • 5.4.1 North America
      • United States
      • Canada
      • Mexico
    • 5.4.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.4.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • GCC
      • South Africa
      • Rest of Middle-East and Africa
    • 5.4.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Novartis International AG
    • 6.1.2 BrainStorm Cell Limited.
    • 6.1.3 Caladrius Biosciences Inc.
    • 6.1.4 Cytori Therapeutics Inc.
    • 6.1.5 Dendreon Pharmaceuticals LLC
    • 6.1.6 Castle Creek Biosciences Inc.
    • 6.1.7 Pharmicell Co. Ltd
    • 6.1.8 Regeneus Ltd
    • 6.1.9 U.S. Stem Cell, Inc.
    • 6.1.10 Gilead Sciences Inc.